Introduction
============

According to the World Health Organization report in 2013, \~440,000 people (aged 15--49 years) are living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in Thailand.[@b1-pgpm-8-163] Thailand has the highest adult HIV prevalence in the Southeast Asian region (1.1%), which leads HIV infection to become one of the major public health problems.[@b1-pgpm-8-163] However, successful HIV transmission prevention and treatment efforts throughout the past 2 decades have reduced the number of annual new HIV infections from 143,000 in 1991 to 9,700 in 2011.[@b2-pgpm-8-163] According to the 2012 Global AIDS Response country progress report for Thailand, \~225,272 (64.6%) eligible adults and children living with HIV and AIDS are on antiretroviral therapy.[@b3-pgpm-8-163] Nevertheless, antiretroviral drug (ARV) toxicity is significant and needs to be monitored. Impaired adherence, which is usually a consequence of persistent adverse drug reactions (ADRs) related to ARV, leads to suboptimal therapy such as therapy discontinuation and ultimately to treatment failure. Treatment failure is often causing significant morbidity and occasionally leading to mortality.[@b4-pgpm-8-163],[@b5-pgpm-8-163] The present knowledge reveals some adverse effects of ARV such as efavirenz (EFV) and abacavir being involved in individual genetic predisposition. There is individual variability in the disposition of ARV, and some of this variability may be caused by variant drug metabolism or transporter genes. Pharmacogenetic research is the study of variations in genes that predict the patient's drug reactions. The benefits of pharmacogenetic testing are guiding the initial drug regimen, increasing efficacy, and simultaneously avoiding ADRs.[@b6-pgpm-8-163]

Cytochrome P (*CYP*) *2B6* genotyping appears to be a promising approach toward the prediction of EFV toxicity and allows the recognition of patients being slow EFV metabolizers.[@b7-pgpm-8-163] Patients who have slow-metabolizing alleles are at risk of greater plasma exposure, central nervous system (CNS) side effects, and possibly EFV resistance after drug withdrawal.[@b7-pgpm-8-163] The CNS side effects range from headaches and dizziness to insomnia, hallucinations, acute mania, and psychosis.[@b8-pgpm-8-163] In a previous study that demonstrated outcome of 139 Thai patients coinfected with HIV and tuberculosis, *CYP2B6* haplotype \*1/\*1 was associated with low EFV concentration.[@b9-pgpm-8-163] In addition, *CYP2B6* haplotypes \*6/\*6, \*1/\*6, and \*5/\*6 were associated with high EFV concentration.[@b9-pgpm-8-163] Other three previous studies in HIV-infected Thai patients showed that the heterozygous/homozygous mutation associated with low EFV concentrations was 18492T\>C, and those associated with high EFV concentrations were 516G\>T, 785A\>G, and 21563C\>T.[@b8-pgpm-8-163]--[@b10-pgpm-8-163]

In 5%--8% of patients initiating abacavir, a drug hypersensitivity reaction can develop within 6 weeks of treatment initiation.[@b11-pgpm-8-163],[@b12-pgpm-8-163] The routine screening of patients' genetic makeup before they are prescribed abacavir has markedly reduced the incidence of hypersensitivity reactions.[@b13-pgpm-8-163] Indeed, in the larger study, the association between human leukocyte antigen-B\* (*HLA-B*\*) *5701* and abacavir hypersensitivity was confirmed in white people but not in Asian subjects.[@b11-pgpm-8-163] According to Thai guidelines by Thai AIDS Society, *HLA-B\*5701* screening prior to starting therapy with abacavir was recommended.[@b14-pgpm-8-163] However, this laboratory testing is not widely available in Thailand due to high cost and limited infrastructure.

Other haplotypes associated with pharmacogenetics and adverse effects among HIV-infected Thai patients are *HLA-B\*4001* and *HLA-B\*3505*. *HLA-B\*4001* is a genetic marker significantly associated with stavudine-associated lipodystrophy.[@b15-pgpm-8-163] *HLA-B\*4001* has a high specificity (95.8%) and a positive predictive value (88.9%). This genetic factor is indeed stronger than the factor of stavudine treatment duration (odds ratio: 9.26 vs 1.02, 95% confidence interval: 1.98--88.11, *P*=0.001).[@b15-pgpm-8-163] Nevirapine (NVP) is still one of the common drugs used in resource-limited setting; however, the incidence of NVP-induced skin rash is as high as 21%--38% in Thailand.[@b16-pgpm-8-163] *HLA-B\*3505* is a strong genetic biomarker for identifying patients with high risk of NVP-induced skin rash in Thai populations (positive predictive value 92.6% and specificity 98.9%). *HLA-B\*3505* genetic test before the administration of NVP is expected to prevent a subset of patients from developing NVP-induced skin rash.[@b17-pgpm-8-163]

In 2010, pharmacogenetic laboratory has been established at Faculty of Medicine Ramathibodi Hospital. We have \~1,500 HIV-infected patients who are under follow-up at the hospital. Of these, 1,200 patients were receiving antiretroviral therapy. However, there are no data after the availability of these tests regarding their use in clinical practice for the treatment of HIV infection in Thailand. Thus, the aims of this study were to describe the use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection and to determine the treatment outcomes of HIV-infected patients in whom pharmacogenetic testing was performed.

Methods
=======

This is a descriptive study of HIV-infected patients attending Ramathibodi Hospital, Bangkok, Thailand. All HIV-infected patients aged \>15 years, attended infectious diseases clinic during January 2011 to November 2014, and in whom pharmacogenetic testing was performed were included in the study. We collected patients' demographic information, reasons for pharmacogenetic testing, symptoms of ADR (such as dizziness, insomnia or depression, skin rash, and fatigue), and the results of *HLA-B\*5701*, *HLA-B\*3505*, *HLA-B\*4001*, *CYP2B6*, and ARV levels. Other laboratory investigation reports were also collected for the following: CD4 cell count, HIV RNA, complete blood count, liver function test (alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin), and serum creatinine. Treatment planning after the physicians were informed the results, and outcome after changing the treatment were retrieved and reviewed. The study was approved by the ethical clearance committee on human rights related to research involving human subjects of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (protocol number ID 08-56-03).

Genomic DNA extraction
----------------------

Blood samples were collected in ethylenediaminetetraacetic acid (EDTA) tubes. DNA was isolated using the MagNA Pure automated extraction system (Roche Diagnostics, Indianapolis, IN, USA), which uses magnetic bead technology with a lysis buffer and proteinase K. Nucleic acids bind to the surface of the magnetic glass particles. Cellular debris was removed by several washing steps, and the purified nucleic acids were eluted. From the 1 mL input volume of EDTA whole blood, 200 μL output volume of extracted genomic DNA product was obtained. The quality of genomic DNA was assessed by using NanoDrop^®^ ND-1000. Genomic DNA was detected by measuring absorbance at 260 nm. Purity of the sample was evaluated by calculation of the optical density (OD) ratio, 260/280 nm. The recommended purified genomic DNA template for this study was 20 ng, and the OD ratio was \>1.7. All DNA was aliquoted and stored at −20°C before analysis.

*HLA-B* typing
--------------

*HLA-B* genotyping was carried out using the Luminex™ Multiplex Technology (Luminex^®^IS 100, Luminex Corporation, Austin, TX, USA) based on polymerase chain reaction (PCR) sequence-specific oligonucleotides probe principles. Briefly, the PCR products were hybridized against a panel of oligonucleotide probes coated onto polystyrene microspheres. Probe sequences were complementary to stretches of polymorphic sequence within the target *HLA-B* alleles. The amplicon--probe complex was visualized using a colorimetric reaction and fluorescence detection technology. Data analyses for the *HLA-B* assays were performed with HLA Fusion™ 2.0 software.

*CYP2B6* genotyping
-------------------

Predesigned TaqMan assays (Thermo Fisher Scientific, Waltham, MA, USA) were used to genotype the *CYP2B6* c.516G\>T (assay ID C_7817765_60), c.64C\>T (assay ID C_2818162_20), c.499C\>G (assay ID C_2752377_10), c.1375A\>G (assay ID C_2741754_10), c.1459C\>T (assay ID C_30634242_40), g.3003T\>C (assay ID C_2818167_10), and g.21563C\>T (assay ID C_22275631_10). The genotyping of *CYP2B6* c.785A\>G was performed by custom TaqMan assays (Applied Biosystems). The sequences of primers and probes were the following: *CYP2B6* c.785A\>G, TGGAGAAGCACCGTGAAACC (forward), TGGAGCAGGTAGGTGTCGAT (reverse), VIC-CCCCCA-AGGACCTC-MGB (wild-type), and FAM-CCCCAGGGAC-CTC-MGB (mutant). For single-nucleotide polymorphism (SNP) analysis, this SNP was genotyped using allele-specific fluorogenic 5′ nuclease chain reaction assay with predesigned primers and TaqMan MGB probes (TaqMan SNP Genotyping Assay; Thermo Fisher Scientific). Sequence-specific forward and reverse primers to amplify the polymorphic sequence of interest used two TaqMan MGB probes; one probe was labeled with VIC dye and detected the allele 1 sequence, and the second probe was labeled with FAM dye and detected the allele 2 sequence.

Measurement of EFV plasma concentrations
----------------------------------------

Plasma EFV level at 12 hours after dosing was measured using a validated high-performance liquid chromatography (HPLC) assay. Briefly, patient plasma samples (300 μL) and all calibration and control samples were heat-inactivated in a water bath at 56°C for 30 minutes prior to assay. Sample pretreatment involved protein precipitation with acetonitrile (360 μL), and following centrifugation, the sample supernatant was injected into the HPLC machine. Analysis was performed using an Agilent 1100 HPLC machine with an Omnispher C18 (150 mm × 4.6 mm ID/particle size 5 μm) analytical column (Varian, Palo Alto, CA, USA), a ChromGuard RP guard column, and a mobile phase consisting of 10 mM KH~2~PO~4~ (pH 3.1)--acetonitrile (50:50, v/v). The retention time for EFV was 5.1 minutes. The peak of this compound was well resolved and free of interference from endogenous compounds in the plasma. The lower limit of quantification of EFV is 0.2 mg/L. The detection limit was defined as a signal-to-noise ratio of 3:1. The calibration standards for plasma samples were linear in the range of 0.2--20 mg/L. Low-, medium-, and high-level quality control (QC) samples were prepared at 0.4 mg/L, 1.5 mg/L, and 10 mg/L, respectively. The intra- and inter-day precision was within 0.0758% and 0.0091%, respectively. The assay accuracy was 93%--104%.

Measurement of NVP plasma concentrations
----------------------------------------

Calibration samples were prepared by spiking 90 μL of blank plasma with 10 μL of the different working standards to produce the matrix-matched calibration standards at concentrations of 100 ng/mL, 200 ng/mL, 500 ng/mL, 1,000 ng/mL, 2,000 ng/mL, 3,000 ng/mL, 5,000 ng/mL, and 10,000 ng/mL of NVP. Each sample also contained 3,000 ng/mL of the internal standard (IS). In each calibration run, a plasma blank sample was also analyzed.

QC samples were prepared at three different concentration levels: low level (75 ng/mL), middle level (250 ng/mL), and high level (4,000 ng/mL). QC samples were prepared by spiking 90 μL of blank plasma with 10 μL of a standard solution. Each QC sample also contained 3,000 ng/mL of the IS.

EDTA blood samples were immediately centrifuged at 3,000 rpm for 15 minutes at 4°C to separate the plasma, and an aliquot of 100 μL of plasma sample was transferred to 1.5 mL tube. Each clinical plasma sample also contained 3,000 ng/mL of the IS.

Calibration, QC, and clinical plasma samples were extracted by protein precipitation. To all of the solutions was added 200 μL of acetonitrile, and then, the mixtures were vortexed for 1 minute and centrifuged for 5 minutes at 15,000 rpm. The organic layer was removed and evaporated to dryness using evaporator at 45°C. The residue was redissolved in 100 μL mobile phase. The mixture was vortexed for 1 minute and centrifuged for 5 minutes at 15,000 rpm. Supernatant was transferred to a vial before injecting into the liquid chromatography--tandem mass spectrometry system.

Definition
----------

-   Therapeutic range of EFV is 1--4 μg/mL.[@b18-pgpm-8-163]

-   Therapeutic range of NVP is 3.7--5.7 μg/mL.

-   Acute kidney injury is defined as any of the following (not graded): increase in serum creatinine by ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours; or increase in serum creatinine by ≥1.5 times of baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume \<0.5 mL/kg/h for 6 hours.[@b19-pgpm-8-163]

-   Anemia is defined as decrease in red blood cell mass: hematocrit \<41% or hemoglobin \<13.5 g/dL in men and hematocrit \<36% or hemoglobin \<12 g/dL in women.[@b20-pgpm-8-163]

-   Lipodystrophy is defined as abnormal or degenerative conditions of the body's adipose tissue which can be evaluated when three body areas are affected: sunken cheeks, thinning extremities, and thinning hips or buttocks.[@b15-pgpm-8-163]

Statistical analysis
--------------------

All relevant data were entered in Microsoft excel database. Missing data were treated as missing in the analysis. The data were analyzed using the statistical program Stata statistical software version 12.0 (StataCorp LP, College Station, TX, USA). Mean (± standard deviation), median (interquartile range), and frequencies (%) were used to describe patients' characteristics.

Results
=======

During the study period, a total of 103 HIV-infected patients with a median age of 46 (range, 20--85) years were enrolled, and 68.9% of them were male. Median CD4 cell count at pharmacogenetic testing was 329 (range, 11--1,121) cells/mm^3^. Most of them (97%) were on ARV, and more than half had undetectable HIV RNA at the end of the study. The most common ARV regimen was tenofovir, lamivudine, and EFV (25%). Patient characteristics are summarized in [Table 1](#t1-pgpm-8-163){ref-type="table"}.

The reasons for pharmacogenetic testing were having ADRs besides rash (37.9%), screening before prescribing ARV (36.9%), choice of the next ARV (19.4%), and confirmation of the cause of skin rash (5.8%). Among 79 patients in whom *HLA* testing was performed, the prevalence of *HLA-B\*5701*, *HLA-B\*3505*, and *HLA-B\*4001* was 5.1%, 2.5%, and 6.3%, respectively ([Table 2](#t2-pgpm-8-163){ref-type="table"}). Two out of four patients who had positive *HLA-B\*5701* developed hypersensitivity after receiving abacavir (two of them received another ARV). One out of five patients who undergone *HLA-B\*4001* genotyping developed lipodystrophy after receiving stavudine (four of them did not receive stavudine). One out of two patients who had positive *HLA-B\*3505* developed skin rash after receiving NVP (the other one did not receive NVP).

Among 51 patients in whom *CYP2B6* genotyping was performed for the management and/or prevention of EFV toxicity, 39.2% were extensive metabolizers. The most common *CYP2B6* haplotypes were *CYP2B6\*1/\*1*, *CYP2B6\*1/\*4*, and *CYP2B6\*1/\*2* with heterozygous mutant g.21563C\>T (CT). Of these, 51.0% were intermediate metabolizers. The most common *CYP2B6* haplotypes were *CYP2B6\*1/\*6*, *CYP2B6\*1/\*2* with heterozygous mutant g.18492T\>C (TC), *CYP2B6\*1/\*5* with homozygous mutant g.18492T\>C (CC), *CYP2B6\*2/\*4* with mutations, and *CYP2B6\*2/\*6* with mutations. The other 9.8% were slow metabolizers. Six out of 51 patients in whom *CYP2B6* genotyping was performed had more than one mutation, five patients had two mutations, and one patient had three mutations.

Three out of five patients who were slow metabolizers had high EFV level (4.246 μg/mL, 7.090 μg/mL, and 4.013 μg/mL). The *CYP2B6* haplotypes of three patients were *CYP2B6\*6/\*6*+ homozygous mutant g.3003CC+g.18492CC+g.21563TT, *CYP2B6\*6/\*6*, and *CYP2B6\*6/\*6*. One patient did not undergo testing of EFV level. The last patient had *CYP2B6\*6/\*6*+ heterozygous mutant g.18492T\>C (TC), but the EFV level was normal (2.093 μg/mL). The *CYP2B6* haplotypes and mutations of *CYP2B6* are shown in [Tables 3](#t3-pgpm-8-163){ref-type="table"} and [4](#t4-pgpm-8-163){ref-type="table"}.

Regarding ADRs, 45 ADRs were skin rash. They could be categorized as 18 ADRs from tenofovir, 17 ADRs from EFV, four ADRs from zidovudine, two ADRs from abacavir, and one ADR each from NVP, raltegravir, ritonavir, and didanosine. Among other ADRs, the most common one of each drug was as follows: acute kidney injury from tenofovir, dizziness from EFV, anemia from zidovudine, hypersensitivity reaction from abacavir, and drug rash from NVP.

Out of a total of 103 patients, the treatment plan, including changing the drug regimens (n=48), changing ARV dose for avoiding toxicity (n=2), and stopping ARV (n=1), was adjusted after the physicians knew the results. ADRs, such as dizziness, insomnia, or depression from EFV or skin rash from abacavir, EFV, or NVP, were improved in 96.4% of patients with these complaints. Abnormal laboratory results, such as acute kidney injury or anemia, were improved which returned to normal or baseline in 59.3% of patients. HIV RNA was undetectable (\<40 copies/mL) after adjusting the treatment in 94.9%.

Discussion
==========

This research is the study describing the use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand, a resource-limited country. We found that the prevalence of *HLA-B\*5701*, *HLA-B\*3505*, and *HLA-B\*4001* was 5.1%, 2.5%, and 6.3%, respectively. Regarding the results of *CYP2B6*, 39.2% were extensive metabolizers, 51.0% were intermediate metabolizers, and 9.8% were slow metabolizers. Finally, we found that when the physicians modified treatment based on pharmacogenetic data, the treatment outcome was improved. In future, this data will be useful for the integration of pharmacogenetic testing into part of HIV clinical management of Thai National Health Care system.

The *HLA* markers *HLA-B\*5701*, *HLA-DR7*, and *HLA-DQ3* were reported to have positive predictive value for abacavir hypersensitivity of 100%.[@b21-pgpm-8-163] *HLA-B\*5701* prevalence in the present study was 5.1% which was comparable to that of the study in Thailand, 4%--10%.[@b22-pgpm-8-163] Low prevalence of *HLA-B\*5701* of 2.5% (95% confidence interval 3.0%--8.7%) was determined among HIV-infected Thai children.[@b23-pgpm-8-163] *HLA-B\*5701* screening is recommended prior to initiating abacavir, especially in population with high prevalence or prevalence \>5% in some studies.[@b23-pgpm-8-163],[@b24-pgpm-8-163] However, it is not widely accessible in the resource-limited countries.[@b25-pgpm-8-163] According to our information obtained, routine screening for *HLA-B\*5701* in Thailand prior to initiating abacavir should be performed because prevalence was \>5%.

In comparison with previous study, *HLA-B\*3505* prevalence in the present study was higher than in general Thai population (2.5% vs 0.7%).[@b26-pgpm-8-163] The previous study in HIV-infected Thai patients determined that *HLA-B\*3505* had a positive predictive value for NVP-induced skin rash of 17.5%.[@b17-pgpm-8-163] In the present study, we identified that one out of two patients (50%) with positive *HLA-B\*3505* developed NVP-induced skin rash. HIV-infected patients in Asia who had late HIV diagnosis usually have polypharmacy. The common drugs that the patients often receive together at the point of ARV initiation are drug(s) for opportunistic infection (OI) prophylaxis (eg, co-trimoxazole and fluconazole) and drug(s) for treatment of OI(s) (eg, antituberculous drug). If *HLA-B\*3505* can identify NVP-induced skin rash in Thai patients, the pharmacogenetic testing can help the physicians to confirm the diagnosis of skin rash from NVP. The modification of HIV management might be easier.

In this study, we determined a higher level of *CYP2B6\*6/\*6* prevalence (9.8%) than the previous larger study (6.6%) in Thai patients coinfected with HIV and tuberculosis.[@b9-pgpm-8-163] The \*6 allele is associated with higher EFV plasma concentrations and an increased risk of CNS toxicity.[@b8-pgpm-8-163] Three out of five patients who were slow metabolizers had high level of EFV. One patient who had *CYP2B6\*6/\*6*+ heterozygous mutant g.18492T\>C (TC) had normal EFV level. This might be explained by the 18492T\>C mutation associated with low EFV concentrations. In patients who had normal and low EFV level, confirmation of EFV level is recommended.

The strength of this study was that it was conducted in a resource-limited country, Thailand, which has the highest prevalence in Southeast Asia. There is only scanty information available regarding pharmacogenetics in clinical practice studies in resource-limited setting including Thailand; this study may lead to the implication of the test in real life.

However, there were several limitations. A major limitation was due to a small number of the study population. In addition, several biases in selection of patients were possible because of nature of retrospective analysis. Difference in economic status might be another bias because only in patients who were government officers or self-paid, pharmacogenetic testing could be performed. Lastly, the majority of HIV-infected patients in this study were male, and sex discrepancy may affect pharmacogenetic result. Due to all these limitations, the results from this study may not be applicable to general population until validation from prospective study with a larger sample size is obtained.

Conclusion
==========

In conclusion, pharmacogenetic tests and therapeutic drug monitoring lead to improvement of medical treatment by creating individualized dosing regimen, maximizing drug efficacy, and minimizing drug toxicity. Benefits of pharmacogenetic screening in HIV patients help to not only reduce ADRs but also minimize HIV drug resistance. In future, the pharmacogenetic testing may be available in more hospitals and cheaper or free of charge for screening all HIV-infected Thai patients to improve quality of care.

**Disclosure**

The authors report no conflicts of interest in this work.

###### 

Demographic and baseline characteristics of 103 HIV-infected patients who performed pharmacogenetic testing

  Variables                                         
  ------------------------------------------------- -----------------------
  Median (range) age at time of diagnosis (years)   46 (20--85)
  Sex, n (%)                                        
   Male                                             71 (68.9)
   Female                                           32 (31.1)
  At pharmacogenetic testing                        
   Median (range) HIV RNA (copies/mL)               8,261 (19--2,670,000)
    Undetectable (\<40 copies/mL), n (%)            54 (52.4)
    Detectable, n (%)                               29 (28.2)
    No data, n (%)                                  20 (19.4)
  After pharmacogenetic testing                     
   Median (range) HIV RNA (copies/mL)               39 (19--610,068)
    Undetectable (\<40 copies/mL), n (%)            76 (73.8)
    Detectable, n (%)                               17 (16.5)
    No data, n (%)                                  10 (9.7)
  At pharmacogenetic testing                        
   Median (range) CD4 cell count (cells/mm^3^)      329 (11--1,121)
    ≤200                                            25 (24.3)
    201--350                                        31 (30.1)
    351--500                                        23 (22.3)
    \>500                                           19 (18.4)
    No data                                         5 (4.9)
  After pharmacogenetic testing                     
   Median (range) CD4 cell count (cells/mm^3^)      404 (19--1,073)
     ≤200                                           13 (12.6)
    201--350                                        18 (17.4)
    351--500                                        33 (32.0)
    \>500                                           32 (31.1)
    No data                                         7 (6.80)
  Treatment status at the end of the study          
   Naive, n (%)                                     2 (2.0)
   On antiretroviral therapy, n (%)                 100 (97.1)
    Tenofovir, lamivudine, efavirenz, n (%)         26 (25.2)
    Tenofovir, emtricitabine, efavirenz, n (%)      22 (21.4)
    Zidovudine, lamivudine, nevirapine, n (%)       7 (6.8)
    No data, n (%)                                  1 (0.9)

**Abbreviation:** HIV, human immunodeficiency virus.

###### 

Number and prevalence of *HLA-B* genotypes in 79 HIV-infected patients

                                           *HLA-B*\*                     
  ---------------------------------------- ----------- ----- ----- ----- ------
  Screening, n                             7           0     0     2     13
  Confirmation the cause of skin rash, n   0           1     2     1     2
  ADRs besides rash, n                     16          1     0     1     12
  Choice of next ARV, n                    8           0     2     1     10
  Total, n                                 31          2     4     5     37
  Prevalence (%)                           39.2        2.5   5.1   6.3   46.8

**Abbreviations:** ADRs, adverse drug reactions; ARV, antiretroviral drug; HIV, human immunodeficiency virus; *HLA-B*\*, human leukocyte antigen-B\*.

###### 

Prevalence of *CYP2B6* predicted phenotypes in 51 HIV-infected patients

                                              *CYP2B6*          
  ------------------------------------------- ---------- ------ -----
  Screening, n                                11         17     1
  Confirmation of the cause of skin rash, n   1          2      1
  ADRs besides rash, n                        6          7      3
  Choice of next ARV, n                       2          0      0
  Total, n                                    20         26     5
  Prevalence (%)                              39.2       51.0   9.8

**Abbreviations:** ADRs, adverse drug reactions; ARV, antiretroviral drug; *CYP2B6*, cytochrome P 2B6; HIV, human immunodeficiency virus.

###### 

Prevalence of *CYP2B6* genotypes and predicted phenotypes in 51 HIV-infected patients stratified by the reasons of testing

  Reasons and results                            *CYP2B6* polymorphisms                 
  ---------------------------------------------- ------------------------ ------ ------ -----
  Screening (n=38)                                                                      
   Extensive metabolizer, n                      2                        8      1      1
   Intermediate metabolizer, n                   3                        12     3      1
   Slow metabolizer, n                           --                       1      --     --
   No *CYP2B6*, n                                --                       --     --     --
  Confirmation of the cause of skin rash (n=6)                                          
   Extensive metabolizer, n                      1                        --     --     --
   Intermediate metabolizer, n                   1                        --     --     1
   Slow metabolizer, n                           1                        --     --     --
   No *CYP2B6*, n                                --                       --     --     --
  ADRs besides rash (n=39)                                                              
   Extensive metabolizer, n                      1                        5      --     --
   Intermediate metabolizer, n                   1                        5      2      1
   Slow metabolizer, n                           2                        1      1      1
   No *CYP2B6*, n                                --                       --     --     --
  Choice of next ARV (n=20)                                                             
   Extensive metabolizer, n                      1                        1      --     --
   Intermediate metabolizer, n                   --                       --     --     --
   Slow metabolizer, n                           --                       --     --     --
   No *CYP2B6*, n                                --                       --     --     --
  Total, n                                       13                       33     7      5
  Prevalence (%)                                 22.4                     56.9   12.1   8.6

**Note:** Five patients had two mutations, and one patient had three mutations.

**Abbreviations:** ADRs, adverse drug reactions; ARV, antiretroviral drug; *CYP2B6*, cytochrome P 2B6; HIV, human immunodeficiency virus.
